SCHEMBL7070244

SCHEMBL7070244

CCOC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1C(c2ccccc2)CCN1S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
GAA P10253 2/20 0.49
TSHR P16473 1/20 0.49
ITGA4 P13612 5/20 0.48
ITGB1 P05556 4/20 0.46
ITGB7 P26010 1/20 0.44
FKBP1A P62942 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
CAPN1 P07384 1/20 0.42
CTSB P07858 1/20 0.42
KMT2A Q03164 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7066161 0.91 ALDH1A1 (0.66) ALDH1A1ITGA4ITGB1ITGB7FKBP1A
SCHEMBL7070251 0.91 ALDH1A1 (0.66) ALDH1A1ITGA4ITGB1ITGB7FKBP1A
SCHEMBL7405577 0.84 ALDH1A1 (0.55) ALDH1A1ITGA4ITGB1ITGB7KMT2A
SCHEMBL7066178 0.84 ALDH1A1 (0.55) ALDH1A1ITGA4ITGB1ITGB7KMT2A
SCHEMBL7070631 0.84 ITGA4 (0.64) ALDH1A1GAATSHRITGA4ITGB1
SCHEMBL20349859 0.79 ALDH1A1 (0.52) ALDH1A1GAATSHRITGA4ITGB1
SCHEMBL20194646 0.79 ALDH1A1 (0.52) ALDH1A1GAATSHRITGA4ITGB1
SCHEMBL7070012 0.78 FKBP1A (0.59) ALDH1A1GAATSHRITGA4ITGB1
SCHEMBL7069024 0.77 MEN1 (0.54) ALDH1A1ITGA4ITGB1CAPN1CTSB
SCHEMBL7067376 0.76 NPSR1 (0.59) ALDH1A1GAATSHRFKBP1AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030065193-A1 Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2003-04-03 US claimed
US-6362341-B1 ANTIINFLAMMATORY AGENTS ATHENA NEUROSCIENCES, INC. 2002-03-26 US claimed
EP-1001975-A1 BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 Elan Pharmaceuticals, Inc. (US) 2000-05-24 EP claimed
WO-1999006436-A1 BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 1999-02-11 WO claimed
US-6586602-B2 CD antigen antagonists such as N-(methanesulfonyl)-L-prolyl-L-phenylalanine and prodrugs used as antiinflammatory agents BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2003-07-01 US disclosed
US-20030065193-A1 Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2003-04-03 US disclosed
US-6362341-B1 ANTIINFLAMMATORY AGENTS ATHENA NEUROSCIENCES, INC. 2002-03-26 US disclosed
EP-1001975-A1 BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 Elan Pharmaceuticals, Inc. (US) 2000-05-24 EP disclosed
WO-1999006436-A1 BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 1999-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065193-A1 Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 VCAM1, ICAM1, ITGB4 ALDH1A1 369/4885GAA 1617/4885TSHR 3702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.